The purpose of this study is to monitor safety outcomes for patients being treated with intravitreal aflibercept injections for choroidal neovascularization secondary to Presumed Ocular Histoplasmosis Syndrome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Southeast Retina
Augusta, Georgia, United States
RECRUITINGRetina Associates of Kentucky
Lexington, Kentucky, United States
RECRUITINGCincinnati Eye Institute
Cincinnati, Ohio, United States
RECRUITINGocular and systemic adverse events
The primary objective of the study is the incidence and severity of ocular and systemic adverse events through Month 12
Time frame: through Month 12
Visual acuity
* Mean change in BCVA from Baseline * Proportion of subjects gaining \>5,10 and 15 letters * Proportion of subjects losing \>5, 10 and 15 letters
Time frame: Months 3, 6, 9 and 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.